What are Igm Biosciences Inc's Business Segments?
Segments: Igm Biosciences Inc operates in the biotechnology and pharmaceutical industry. The company primarily focuses on the development of immunoglobulin M (IgM) antibodies for the treatment of various diseases. The company is engaged in the research and development, manufacturing, and commercialization of IgM drugs.
Products: 1. IGM-2323: It is a bispecific antibody that targets CD20 and CD3 for the treatment of B cell malignancies. The product is currently in phase 1 clinical trials.
2. IGM-8444: It is a bispecific antibody that targets PD-L1 and LAG-3 for the treatment of various cancers. The product is in preclinical development.
3. IGM-7354: It is a bispecific antibody that targets CD47 and CD19 for the treatment of B cell malignancies. The product is in preclinical development.
4. IGM-7650: It is a bispecific antibody that targets CD20 and CD47 for the treatment of B cell malignancies. The product is in preclinical development.
Services: Igm Biosciences Inc is primarily focused on the development of novel IgM antibodies for the treatment of cancers and various diseases. The company offers the following services:
1. Research and Development: The company offers research and development services to develop novel IgM antibodies for the treatment of various diseases.
2. Manufacturing: The company provides manufacturing services for the production of IgM antibodies for clinical and commercial use.
3. Clinical Trials: The company offers clinical trial services for the testing of its IgM antibodies in humans.
4. Regulatory Affairs: The company offers regulatory affairs services for the approval of its IgM antibody products by regulatory authorities.
|